Monopar Therapeutics Inc.
MNPR
$43.15
$1.333.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.22% | -21.20% | -10.32% | -13.12% | 8.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 479.22% | -23.77% | -23.17% | -31.75% | -34.27% |
| Operating Income | -479.22% | 23.77% | 23.17% | 31.75% | 34.27% |
| Income Before Tax | -502.33% | 33.24% | 22.03% | 32.59% | 37.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -502.33% | 33.24% | 22.03% | 32.59% | 37.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -502.33% | 33.24% | 22.03% | 32.59% | 37.37% |
| EBIT | -479.22% | 23.77% | 23.17% | 31.75% | 34.27% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -259.71% | 46.45% | 40.26% | 44.71% | 44.90% |
| Normalized Basic EPS | -259.71% | 46.44% | 40.27% | 44.70% | 44.90% |
| EPS Diluted | -259.71% | 46.45% | 40.26% | 44.71% | 45.29% |
| Normalized Diluted EPS | -259.71% | 46.44% | 40.27% | 44.70% | 44.90% |
| Average Basic Shares Outstanding | 67.44% | 24.67% | 30.51% | 21.93% | 13.67% |
| Average Diluted Shares Outstanding | 67.44% | 24.67% | 30.51% | 21.93% | 13.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |